Oculis Holding AG OCS

Oculis Holding AG is a global late clinical stage biopharmaceutical company headquartered in Switzerland with operations in Switzerland, the United States, and Iceland. The company focuses on developing therapeutics for neuro ophthalmic and ophthalmic diseases. Its pipeline includes three clinical stage candidates: OCS 01 for diabetic macular edema, Licaminlimab for dry eye disease, and Privosegtor for optic neuritis and non arteritic anterior ischemic optic neuropathy. OCS 01 is an eye drop formulation of dexamethasone that uses the proprietary OPTIREACH technology to improve drug solubility and retinal penetration; it is being evaluated in two global Phase 3 trials for diabetic macular edema with topline results expected in the second quarter of 2026. Licaminlimab is a single chain antibody fragment targeting tumor necrosis factor alpha formulated as an eye drop for dry eye disease; it is being studied in a Phase 2/3 trial with a genotype based approach with topline results anticipated in the fourth quarter of 2026. Privosegtor is a peptoid small molecule that penetrates the blood retinal and brain barriers to provide neuroprotection; it is being evaluated in Phase 2/3 trials for optic neuritis and non arteritic anterior ischemic optic neuropathy with topline results expected in the fourth quarter of 2026. Oculis Holding AG aims to become a leader in these therapeutic areas.

Oculis Holding AG currently does not generate product revenue as its therapeutic candidates remain in clinical development. The company finances its operations primarily through equity financing from investors and has raised approximately CHF 493.6 million since inception through December 31 2025. It has entered into licensing agreements with Novartis for Licaminlimab and with Accure for Privosegtor that may provide future milestone payments and royalty income upon successful commercialization. Under the Novartis agreement the company may owe up to CHF 76.9 million in milestone payments and pay royalties ranging from a mid single digit to a mid teen percentage on net sales. Under the Accure agreement potential milestone obligations could reach CHF 87.9 million with royalties in the mid single digit to low mid teen range. Revenue is expected to arise from product sales after regulatory approval and from these partnership arrangements.

Oculis Holding AG competes with established pharmaceutical and biotechnology companies in the ophthalmology market. For diabetic macular edema it faces competition from Abbvie, ANI Pharmaceuticals, Bayer, Novartis, Regeneron, and Roche among others. For dry eye disease competitors include Abbvie, Alcon, Bausch + Lomb, Viatris, Harrow, and Sun Pharmaceuticals. In neuro ophthalmic indications rivals comprise Amgen, Dompe, Argenx, and Veridian. The diabetic macular edema market in the G7 countries is projected to reach approximately five billion dollars in 2025 while the dry eye disease market is forecast to grow to about seven point three billion dollars by 2029. Optic neuritis and non arteritic anterior ischemic optic neuropathy are rare diseases with high unmet medical need and limited approved treatment options. The company's competitive advantages stem from its proprietary OPTIREACH technology that enables topical delivery of dexamethasone to the retina, its single chain antibody fragment format for Licaminlimb, and its peptoid small molecule Privosegtor which has received Breakthrough Therapy and Orphan Drug designations.

Oculis Holding AG intends to serve patients suffering from diabetic macular edema, dry eye disease, optic neuritis, and non arteritic anterior ischemic optic neuropathy as well as potentially those with multiple sclerosis. In the United States an estimated 1.8 million people have been diagnosed with diabetic macular edema while dry eye disease affects roughly forty million individuals. The annual incidence of optic neuritis is estimated to be greater than thirty thousand cases and non arteritic anterior ischemic optic neuropathy occurs in a similar range. Multiple sclerosis affects approximately two point eight million people worldwide with about eight hundred fifty thousand cases in the United States. Its customers will be patients, ophthalmologists, neuro ophthalmologists, and other health care providers who prescribe or administer the therapies. No specific customer names are disclosed in the filing.